neuropathy. Other disorders of peripheral nervous system
Conditions
Interventions
Intervention 1: Intervention group: duloxetine - Patients who met the criteria for entering the study were entered into the study after randomization, and these patients were entered after neurologica
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients with breast cancer who treated with taxol (paclitaxel) for chemotherapy with peripheral neuropathic and neuropathic pain with confirmation of physical examination pain score 3 or more according to MacGill questionnaire No metastasis life expectancy more than 3 months Hospital anxiety and depression scale score less than 20 according to HADS questionnaire Neuropathic score more than 3 in DN4 questionnaire.
Exclusion criteria
Exclusion criteria: metastatic breast cancer pregnancy and breast feeding HADS score more than 20 using antidepressant and anti epileptic drugs and opioids paralytic neuropathic syndromes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score 3 or more according to MacGill questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: MacGill questionnaire.;Hospital anxiety and depression scale score less than 20 according to HADS questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: HADS questionnaire.;Neuropathic score more than 3 in DN4 questionnaire. Timepoint: At the beginning of the study and 10 weeks after starting the drug. Method of measurement: DN4 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanieh Radkhah
Tehran University of Medical Sciences
Outcome results
None listed